SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech for less than cash value
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: scaram(o)uche1/15/2016 11:24:24 AM
1 Recommendation

Recommended By
DewDiligence_on_SI

  Read Replies (1) of 684
 
cmrx.... just failed/flopped a phase III trial, purportedly due to steroid use in patients....... CMV in hematopoietic cell transplants.

Using 9/30 cash, I get $8.20/share. Book was $391m, or approximately 8.48/share. Burn for qtr was $31m. Current share price $6.91.

Phase III trials enrolling for CMV in kidney transplantation. Earlier study in adenovirus has completed enrollment... historical controls!

BARDA for smallpox. Composition of matter for lead project through 2034.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News